按衰弱分层比较SGLT-2抑制剂、GLP-1受体激动剂与DPP-4抑制剂在2型糖尿病中的心血管有效性与安全性
研究基于2013-2019年Medicare受益人数据,开展三项1:1倾向评分匹配队列研究,按三个衰弱分层比较SGLT-2抑制剂、GLP-1受体激动剂与DPP-4抑制剂在2型糖尿病中的心血管有效性与安全性。结果显示,与DPP-4抑制剂相比,SGLT-2抑制剂和GLP-1受体激动剂均降低主要心血管复合结局风险,且在衰弱人群中绝对获益最大;严重不良事件未见更频繁。
要点
- 与DPP-4抑制剂相比,SGLT-2抑制剂主要有效性结局HR 0.72(95%CI 0.69-0.75),IRD -13.35。
- 与DPP-4抑制剂相比,GLP-1受体激动剂主要有效性结局HR 0.74(95%CI 0.71-0.77),IRD -15.49。
- SGLT-2抑制剂和GLP-1受体激动剂的绝对获益在衰弱人群中最大,严重不良事件未更频繁。
核心结论
- SGLT-2抑制剂和GLP-1受体激动剂安全地改善了心血管结局和全因死亡率,在衰弱人群中绝对获益最大。
研究设计与样本
- 三项1:1倾向评分匹配队列研究,每项按三个衰弱分层,使用2013-2019年Medicare受益人数据,纳入启动SGLT-2抑制剂、GLP-1受体激动剂或DPP-4抑制剂的2型糖尿病老年人。
主要发现
- 与DPP-4抑制剂相比,SGLT-2抑制剂(n=120,202匹配对)主要有效性结局总体HR 0.72(95%CI 0.69-0.75),IRD -13.35(95%CI -15.06至-11.64)。
- SGLT-2抑制剂IRD从非衰弱者的-6.74(95%CI -8.61至-4.87)到衰弱者的-27.24(95%CI -41.64至-12.84)(交互作用P<0.01)。
- 与DPP-4抑制剂相比,GLP-1受体激动剂(n=113,864)总体HR 0.74(95%CI 0.71-0.77),IRD -15.49(95%CI -17.46至-13.52)。
- GLP-1受体激动剂IRD在最低衰弱分层为-7.02(95%CI -9.23至-4.81),最高衰弱分层为-25.88(95%CI -38.30至-13.46)(交互作用P<0.01)。
- SGLT-2抑制剂与GLP-1受体激动剂比较(n=89,865)结果相当;SGLT-2抑制剂或GLP-1受体激动剂的严重不良事件不比DPP-4抑制剂更频繁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the comparative cardiovascular effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase 4 inhibitors (DPP-4is) in older adults with type 2 diabetes (T2D) across different frailty strata. RESEARCH DESIGN AND METHODS: We performed three 1:1 propensity score-matched cohort studies, each stratified by three frailty strata, using data from Medicare beneficiaries (2013-2019) with T2D who initiated SGLT-2is, GLP-1RAs, or DPP-4is. In time-to-event analyses, we assessed the primary cardiovascular effectiveness composite outcome of acute myocardial infarction, ischemic stroke, hospitalization for heart failure, and all-cause mortality. The primary safety outcome was a composite of severe adverse events that have been linked to SGLT-2i or GLP-1RA use. RESULTS: Compared with DPP-4is, the overall hazard ratio (HR) for the primary effectiveness outcome associated with SGLT-2is (n = 120,202 matched pairs) was 0.72 (95% CI 0.69-0.75), corresponding to an incidence rate difference (IRD) of -13.35 (95% CI -15.06 to -11.64). IRD ranged from -6.74 (95% CI -8.61 to -4.87) in nonfrail to -27.24 (95% CI -41.64 to -12.84) in frail people (P for interaction < 0.01). Consistent benefits were observed for GLP-1RAs compared with DPP-4is (n = 113,864), with an overall HR of 0.74 (95% CI 0.71-0.77) and an IRD of -15.49 (95% CI -17.46 to -13.52). IRD in the lowest frailty stratum was -7.02 (95% CI -9.23 to -4.81) and -25.88 (95% CI -38.30 to -13.46) in the highest (P for interaction < 0.01). Results for SGLT-2is versus GLP-1RAs (n = 89,865) were comparable. Severe adverse events were not more frequent with SGLT-2is or GLP-1RAs than DPP-4is. CONCLUSIONS: SGLT-2is and GLP-1RAs safely improved cardiovascular outcomes and all-cause mortality, with the largest absolute benefits among frail people.
引用
- Kutz A, Kim DH, Wexler DJ, et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care. 2023. PMID: 37677118. doi:10.2337/dc23-0671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。